Prof Thierry Facon speaks to ecancer in an online interview for the EHA 2021 virtual meeting about the MAIA study.
This study evaluated daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeolma, with the overall survival results being presented at this point. Initially, he talks about progression-free survival with regards to the drug combination used in this study.
Prof Facon further describes the results of this study in detail. In the end, he discusses the safety profile and efficacy of these drugs.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.